Lineage Cell Therapeutics Inc

ASE:LCTX   12:15:47 AM EDT
-0.02 (-1.06%)
Earnings Announcements

Lineage Cell Therapeutics Inc Reports Q3 Loss Per Share Of $0.04

Published: 11/10/2022 21:20 GMT
Lineage Cell Therapeutics Inc (LCTX) - Lineage Cell Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update.
Total Revenues for Three Months Ended September 30, 2022 Were Approximately $3.0 Million, a Net Increase of $0.7 Million.
Q3 Loss per Share $0.04.
Q3 Earnings per Share View $-0.04, Revenue View $3.9 Million -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $2.57 Million
Adjusted EPS is expected to be -$0.04

Next Quarter Revenue Guidance is expected to be $1.22 Million
Next Quarter EPS Guidance is expected to be -$0.05

More details on our Analysts Page.